title: Hypertension in the oncology setting.
abstract: In the oncology setting, HTN is a common comorbidity and complication of some treatments. A thorough assessment of each patient, including medical history and current medication list, is used to screen for HTN. The Joint National Committee guidelines (National Heart, Lung, and Blood Institute, 2003) have provided a resource for proper selection of medications for management of HTN, with considerations for special populations.
authors.affiliation: Rocky Mountain Cancer Center in Denver, CO, USA. katherine.albert@usoncology.com
authors.forename: Katherine
authors.initials: K
authors.lastname: Albert
mesh_terms: D001741:Black or African American; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000150:complications* / Q000473:pathology / Q000503:physiopathology; D004232:Diuretics / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D015994:Incidence; D017706:Lisinopril / Q000008:administration & dosage / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000556:secondary; D008875:Middle Aged
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics; D006852:Hydrochlorothiazide; D017706:Lisinopril